SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Spekulatius who wrote (421)2/28/2003 12:18:44 AM
From: tuck  Read Replies (2) of 897
 
Ralf,

I know better than to dismiss your suggestions, but MEDI's valuation is comparable to AMGN's. Parallel with Immunex buy, which seemed expensive to me, but they've been able to expand the label on Enbrel. Both their forward PEG ratios look reasonable. However, Enbrel is a proven winner and FluMist is not. Nor does the latter have much room for label expansion unless the FDA can be convinced the safety in younger and older patients is adequate. We know the FDA currently doesn't think so. FluEnsure from IDBE looks promising safety-wise, but the current formulation requires two doses for comparable efficacy, a disadvantage. And it's several years away.

I'd be willing to try it, but I'd be looking for an entry if it busts $30. Of course, waiting for a bounce on Vertex cost plenty. That was a good candidate. Maybe a half position around here, adding to it on unwarranted strength.

Anyone else have a take on MEDI?

Thanks & Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News